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Abstract
Delayed clearance of hepatitis B surface
antigen was previously reported in a 38
year old woman after high dose chemo-
therapy with autologous peripheral blood
stem cell rescue. Sixteen months later,
this patient remained hepatitis B surface
antigen negative, hepatitis B surface anti-
body positive, and serum hepatitis B DNA
negative by polymerase chain reaction.
Serial liver biopsies (one at hepatitis B e
antigen positive stage, one at hepatitis B e
antibody positive stage, and one at hepati-
tis B surface antigen negative and hepati-
tis B surface antibody positive stage)
showed a gradual resolution ofthe inflam-
matory activity with loss of hepatitis B e
antigen and then hepatitis B surface anti-
gen in the serum. However, the degree of
fibrosis, though mild, remained the same.
With the serological clearance of hepatitis
B surface antigen, a small amount of
hepatitis B virus DNA was still detectable
in the nuclei of liver cells.
(_ Clin Pathol 1997;50:706-708)
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Chronic hepatitis B infection (HBV) is a
serious global health problem affecting ap-
proximately 300 million individuals. Of these,
20 to 40 per cent are likely to die of cirrhosis or
hepatocellular carcinoma. Seventy five per cent
ofthe HBV virus carriers are Chinese and most
of them acquire the infection perinatally.
Unfortunately, spontaneous loss of hepatitis B
surface antigen (HBsAg) is a rare occurrence.'
The cause of viral persistence is largely
unknown.2 Previously, we reported our pre-
liminary observation on the delayed clearance
of HBsAg in a 38 year old woman 33 months
after high dose chemotherapy with autologous
peripheral blood stem cell rescue.' Sixteen
months after this serological clearance of
HBsAg, she remains HBsAg negative, hepatitis
B surface antibody (HBsAb) positive, and
HBV DNA negative in serum by both dot
hybridisation and polymerase chain reaction
(PCR). Recently, it was found that traces of
HBV are often detectable in the blood for many
years after clinical recovery from acute
hepatitis.4 In this study, we examined the serial
changes in liver histology before and after
recovery from chronic HBV infection in this
patient, and the hepatic expression of HBV
markers.
Case report
A 40 year old Chinese woman, known to be
HBsAg positive since 1982, was diagnosed as
having non-Hodgkin's lymphoma in December
1984. At that time, she was HBsAg positive,
hepatitis B e antigen (HBeAg) positive, and
serum HBV DNA positive (by dot hybridisa-
tion), with normal liver function tests (serum
alanine aminotransferase 17 IU/l). Seven
courses of chemotherapy consisting of cyclo-
phosphamide, doxorubicin, vincristine, and
prednisone followed by local radiotherapy were
given. This resulted in complete remission of
the lymphoma.
During the treatment period (in December
1985), she had an episode ofHBV reactivation
(peak serum aminotransferase 1932 IU/l) and
liver biopsy at that time showed chronic active
hepatitis (fig 1A). There was marked piecemeal
plus bridging necrosis, marked intralobular
degeneration and focal necrosis, marked portal
inflammation, and fibrous portal expansion.
The histological activity index (HALI) score was
15 (table 1). Immunohistochemistry showed
< 1% of hepatocytes stained positive for both
HBsAg and hepatitis B core antigen (HBcAg).
HBV DNA was positive by in situ hybridisation
in the cytoplasm of 75% of the hepatocytes.
The patient had an uneventful recovery.
In February 1986, she had a lymphoma
recurrence in the right submandibular region
and was given another six courses of chemo-
therapy consisting of epirubicin, vincristine,
cytarabine, prednisolone, and bleomycin, re-
sulting in a second complete remission. During
this second course of chemotherapy, there was
no HBV reactivation and the patient remained
HBsAg positive, HBeAg positive, and HBV
DNA positive by dot hybridisation. In April
1986, she seroconverted from HBeAg positive
to HBeAb positive, with disappearance of
serum HBV DNA by dot hybridisation, though
positivity by PCR persisted.
In December 1990, the lymphoma recurred
in her left cervical lymph nodes. She was given
chemotherapy consisting of ifosphamide,
methotrexate, and etoposide, resulting in a
third complete remission. There was no HBV
reactivation during this third course of chemo-
therapy and she remained HBsAg positive,
HBeAb positive, and serum HBV DNA
negative by dot hybridisation but positive by
PCR. Liver biopsy in March 1991 showed
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Figure 1 (A) Liver section showing marked porta
inflammation with profound piecemeal and bridgin
necrosis (trichrome, x70). (B) Liver section showin
portal inflammation andfibrous portal expansion, 4
piecemeal andfocal necrosis (haematoxylin and eos
xl1 0). (C) Immunohistochemical staining showing
hepatocytes positive for hepatitis B surface antigen ((D) Liver section showing only mild portal inflamn
andfibrous portal expansion with no piecemeal or)
necrosis (haematoxylin and eosin, xl 75).
chronic persistent hepatitis. There wa
piecemeal necrosis, mild intralobular
eration, mild portal inflammation, and:
portal expansion (fig 1B). Immunohistc
istry showed 30% staining for HBsAg a
for HBcAg (fig 1 C). HBV DNA was posi
in situ hybridisation in the cytoplasm of
the cells and 25% of hepatic nuclei. Hig
Table 1 Histological changes of serial liver biopsies
Date of liver biopsy
2247 days 339 days 142
before BMT before BMT afo
Histological variables
Periportal +/- bridging necrosis (0-10) 6 1 0
Interlobular degeneration and focal necrosis (0-4) 4 1 1
Portal inflammation (0-4) 4 1 1
Fibrosis (0-4) 1 1 1
Total histological activity index score 15 4 3
Hepatic expression ofHBV
Immunohistochemistry
HbsAg+/HBeAg+ (%) <1/<1 30/0 0/0
In situ hybridisation
HBV DNA+ (%)
Cytoplasm/nucleus 75/0 50/25 0/<
HBVDNAbyPCR + + +
BMT, bone marrow transplant; HBV, hepatitis B virus; HbsAg, hepatitis B surface
HbeAG, hepatitis B e antigen; PCR, polymerase chain reaction.
chemotherapy consisting of cyclophospha-
mide, carmustine, and etoposide with autolo-
gous peripheral stem cell rescue was given in
.:> February 1992. The peripheral blood stem
cells were collected after granulocyte colony
stimulating factor (G-CSF) mobilisation. The
post-transplantation course was uneventful
Rr|to apart from grade 1 regimen related liver toxic-
ity from day 20 to day 25 (peak bilirubin 33
gmol/l). Her liver function tests remained in
the normal range thereafter. On day 379, she
was HBsAg positive, HBeAg negative, HBeAb
positive, and HBV DNA negative by dot
hybridisation but positive by PCR. In Novem-
ber 1994 (33 months after the high dose
therapy), the patient seroconverted to become
HBsAg negative, HBsAb positive, and serum
HBV DNA negative by both dot hybridisation
and PCR.
A third liver biopsy was performed on 19
March 1996. The histology showed only mild
fatty changes with no piecemeal necrosis, very
mild intralobular degeneration, very mild
portal inflammation, and fibrous portal expan-
sion (fig 1D). There was no HBsAg and
'-_ ,tr HBcAg staining. However, liver cell nuclei
were still positive (< 5% of cells) by in situ
hybridisation, and the liver was positive for
HBV DNA by PCR.
a
Methods used
HEPATITIS SEROLOGY ASSAYS, SERUM AND TISSUE
HBV DNA
Hepatitis B serological markers-HBsAg
1l (Auszyme, monoclonal), HBsAb, HBeAg,
tg HBeAb; hepatitis C virus antibody (EIA II),
Ig mild. hepatitis D virus antibody, and human immu-
'and Id nodeficiency antibody-were all tested using
v 30% of commercially available enzyme immunoassays
X110). (Abbott Laboratories, Chicago, Illinois, USA).
nactln Clearance of HBsAg was confirmed by retest-
ing using the polyclonal assay (Murex, Dart-
s mild ford, England). Serum HBV DNA was de-
degen- tected using dot hybridisation.5 HBV DNA wasdegen- extracted from paraffin embedded liver tissue
)chem- as described by Shindo et al.6 Nested PCR
cnd 0% assay for the detection of serum extracted and
itiv °° tissue extracted HBV DNA was performeditv bf using primer sets from the surface antigen and
5h dof the core antigen coding regions.5
HISTOLOGICAL ASSESSMENT,
IMMUNOHISTOCHEMISTRY, AND IN SITU
HYBRIDISATION
84 days The liver biopsies were assessed under code by
erBMT a pathologist (PCW) who had no prior knowl-
edge of the patient's clinical data or of the
chronological' order of the biopsy specimens.
Chronic hepatitis was graded and staged using
the histological activity index (HAI).' The
amount of HBV antigen in the liver biopsy
samples was determined by standard immuno-
histochemistry (HBsAg, monoclonal antibody,
Biogenex, San Ranom, California, USA;
HBcAg, polyclonal, Dako, Carpentia, Califor-
:5 nia, USA) on paraffin sections. The PAP kit
(Amersham, Chicago, Illinois, USA) was em-
antigen; ployed, with peroxidase as the marker and
diaminobenzidine as the substrate. Hepatic
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HBV DNA was detected by in situ hybridisa-
tion as described previously.'
Discussion
The patient we report here has been followed
up at our clinic for more than 11 years (seven
years before bone marrow transplantation and
more than four years afterwards). This is the
first documented report on the serological
clearance of HBsAg following high dose
chemotherapy and peripheral blood stem cell
rescue. The patient has a definite history of
chronic hepatitis B, as evidenced by previous
serology and histology. The mechanism for her
loss of HBV viral markers7 (HBsAg and HBV
DNA) is unknown. Loss of HBsAg is probably
related to the high dose chemotherapy and
autologous peripheral blood stem cell infusion,
as the chance of spontaneous loss of HBsAg is
extremely low, especially in Chinese (0.1% to
0.8%).
No matter what mechanism was involved,
this report suggests that the cause ofHBV per-
sistence is not clonal deletion but clonal
suppression, as only autologous cells were
involved.3 Hepatitis B e seroconversion oc-
curred more than 300 days before the autolo-
gous bone marrow transplant. This was
accompanied by lowering of HBV DNA in
serum, which could not be detected by dot
hybridisation but only by PCR. Histologically,
even at this stage there was already marked
reduction in necroinflammatory activity. This
lowered HBV DNA level might have helped the
subsequent clearance of HBsAg after autolo-
gous bone marrow transplantation. This is in
analogy to the use of interferon in treating
HBV, where a low HBV DNA level favours
response. Similarly, it was our recent observa-
tion that a high pre-bone marrow transplant
HBV DNA viral load might have prevented one
of our allogeneic bone marrow transplant
patients from clearing HBsAg after reception of
HBsAb positive marrow.5
The loss ofHBsAg occurred 33 months after
the autologous bone marrow transplantation.
This kind of delayed clearance has also been
reported in patients treated with interferon.
With seroconversion from HBeAg to HBeAb
and then from HBsAg to HBsAb, there was
marked resolution of inflammatory compo-
nents (marked piecemeal necrosis and bridging
necrosis observed in the initial liver biopsy).
However, the fibrous portal expansion, though
mild, remained the same throughout the
course. The histological picture probably
represented an inactive burned out form of
chronic active hepatitis.9
Though the patient is HBsAg negative and
HBsAb positive, HBV DNA is still detectable
in the liver tissue by in situ hybridisation and
PCR. This low level ofHBV, which persisted in
the liver, probably represents active virus rather
than integrated, non-replicative forms of ge-
nome. First, recrudescence of hepatitis B has
been reported in HBsAg negative patients who
have been treated with cancer chemotherapy,
immunosuppressive regimens, or liver trans-
plantation.'0 Second, there have been several
reports of transmission of hepatitis B by blood
donations from HBsAg negative patients."
Third, it has been shown that resolution of
HBV infection with the development of
HBsAb does not necessarily mean complete
eradication of the virus. Recently, it was found
that HBV specific cytotoxic T lymphocytes can
be present as acute stage precursors long after
recovery, displaying an activated phenotype
(HLA-DR, CD 69), and can coexist with trace
amounts of HBV DNA. These data suggest
that the hepatitis B virus is controlled by the
cellular and humoral immune response rather
than being completely eradicated after resolu-
tion of acute and chronic hepatitis B infection.4
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